Ruff v. Ensign-Bickford Industries, Inc.

168 F. Supp. 2d 1271, 2001 U.S. Dist. LEXIS 17031, 2001 WL 1329678
CourtDistrict Court, D. Utah
DecidedAugust 27, 2001
Docket2:99-cv-00120
StatusPublished
Cited by3 cases

This text of 168 F. Supp. 2d 1271 (Ruff v. Ensign-Bickford Industries, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ruff v. Ensign-Bickford Industries, Inc., 168 F. Supp. 2d 1271, 2001 U.S. Dist. LEXIS 17031, 2001 WL 1329678 (D. Utah 2001).

Opinion

MEMORANDUM OPINION & ORDER

BENSON, District Judge.

Introduction

This matter is before the Court on defendants’ combined motion for summary judgment and motion to exclude the testimony of plaintiffs’ medical causation expert, Dr. Dennis Weisenburger. Defendants Ensign-Bickford Industries, Inc., the Ensign-Bickford Company, and Mal-linckrodt Inc., jointly filed the instant motion. Also before the Court are plaintiffs’ motions in limine to exclude three of defendants’ medical experts, Dr. Phillip Guzelian, Dr. Robert James and Dr. John Ward. All plaintiffs, Howard Ruff and Kay Ruff, Charles Bates (deceased) and Ellen Bates, Rodney Petersen and Marilyn Petersen, filed joint motions in limine seeking to exclude defendants’ medical experts.

From June 21 to June 26, 2001, the Court held an evidentiary hearing pursuant to Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). The Court has reviewed the testimony and exhibits presented at the evidentiary hearing, the opinions submitted by the expert witnesses, the relevant scientific literature, the briefs supporting and opposing the motions, and the pertinent case law. The Court now issues the following memorandum opinion and order.

Background

Defendants are present and former owners of an explosives manufacturing plant, located at the mouth of Spanish Fork Canyon, one to two miles south of Mapelton, Utah. 1 In June of 1986, one of the plant’s disposal pond liners failed, causing hundreds of thousands of gallons of dilute nitric acid solution to be released into the ground. Three years after the nitrate solution leaked into the ground, the City of Mapleton closed one of its municipal water wells due to high levels of nitrates. Prior to 1986, other contaminants allegedly seeped into the Mapelton groundwater as a result of defendants’ improper hazardous waste disposal practices. Defendants are presently engaged in an expansive remediation effort with the State of Utah’s Division of Water Quality to clean up chemicals which have contaminated certain areas near the plant.

Plaintiffs are or were residents and neighbors in the small community of Ma-pelton. Plaintiffs allege that they have suffered personal injuries from the ingestion of various chemicals which seeped into their private well water from the plant. Each plaintiff has been diagnosed *1274 with cancer, specifically, small cleaved 13-cell follicular non-Hodgkins lymphoma (NHL). Follicular NHL comprises approximately one third of all NHLs, and the small cleaved B-Cell variant comprises only 10% of all NHLs. Mrs. Petersen was diagnosed with NHL in 1984, two years prior to the liner failure at the explosives plant. She was the first of the present plaintiffs to contract cancer. The second plaintiff to develop NHL was Mr. Ruff, who was diagnosed in 1990. Lastly, Mr. Bates learned in 1992 that he had contracted NHL. Mr. Bates recently passed away as a result of complications with NHL.

The chemicals at issue in this litigation have been grouped by the parties into four separate categories: 1) Royal Demolition Explosives (“RDX”), 2) Hydrazines, including 1,1 dimethylhydrazine and 1,2 dime-thylhydrazine, 3) N-nitroso compounds or nitrosamines, including MNRDX, DNRDX, and TNRDX, and 4) Nitrate esters, including EGDN, DEGDN, TMETN, and BTTN. 2 The carcinogenicity of these chemicals and their ability to cause NHL in humans and specifically in each plaintiff are at the heart of this case and the instant motions in limine. If plaintiffs are unable to present credible evidence, through a medical expert, that the above chemicals were more likely than not the cause of their cancer, then summary judgment is appropriate in favor of defendants.

Plaintiffs’ medical causation expert, Dr. Dennis Weisenburger, concluded in his report and testified at the Daubert hearing, that the above chemicals, either singly or in combination, more likely than not caused each of the plaintiffs’ NHL. Defendants’ medical experts, Dr. Phillip Guzeli-an and Dr. Robert James, submitted rebuttal reports and testified at the Daubert hearing for the sole purpose of attacking Dr. Weisenburger’s methodology and conclusions with respect to the causal link between the chemicals at issue and plaintiffs’ NHL. Dr. John Ward, retained by defendants as a medical causation expert, concluded in his expert report and at the Daubert hearing that there are no known causes of NHL in humans. Each of the above experts’ testimony is subject to a motion in limine filed by the opposition. However, the reliability of Dr. Weisenbur-ger’s methodology in reaching his conclusion, that the above chemicals more likely than not caused plaintiffs’ NHL, is the central focus of each expert report and the instant motions.

Discussion

This case presents the issue whether Dr. Weisenburger employed a reliable scientific methodology when concluding that RDX, its break-down products, and nitrates, either singly or in combination, more likely than not caused plaintiffs’ NHL. Defendants argue that Dr. Weisen-burger’s methodology was flawed primarily because of the lack of epidemiologic 3 *1275 evidence demonstrating a link between NHL and the chemicals from defendants’ plant. Plaintiffs counter with Dr. Weisen-burger’s scientific and medical credentials, his extensive research and experience in the relevant area, and with several epidemiological and animal studies that indicate a connection between the chemicals from defendants’ plant and NHL.

In the final analysis the case for the admissibility of Dr. Weisenburger’s opinions under rule 702 presents a challenging set of arguments for the Court, with each side presenting arguments that are thoroughly developed and skillfully argued. In the Court’s final analysis, two factors tip the scale in favor of admissibility. First, as discussed within each chemical section below, the Court finds that defendants overstate the lack of epidemiological data available in favor of plaintiffs’ case, and understate the positive animal data. Second, Dr. Harber’s testimony at the Daubert hearing, that Dr. Weisenburger’s conclusions are based on reliable scientific methodologies and are supported by sufficient facts and data, was particularly helpful and persuasive to the Court. Dr. Harber’s testimony is discussed in further detail below.

Daubert Standard

Federal Rule of Evidence 702 was recently amended in response to Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993) and its progeny. Amended rule 702 provides:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dale K. Barker Co., P.C. v. Sumrall
541 F. App'x 810 (Tenth Circuit, 2013)
Cook v. Rockwell International Corp.
580 F. Supp. 2d 1071 (D. Colorado, 2008)
Miller v. Pfizer, Inc.
196 F. Supp. 2d 1062 (D. Kansas, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
168 F. Supp. 2d 1271, 2001 U.S. Dist. LEXIS 17031, 2001 WL 1329678, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ruff-v-ensign-bickford-industries-inc-utd-2001.